ID Source | ID |
---|---|
PubMed CID | 13619 |
CHEMBL ID | 1569358 |
SCHEMBL ID | 591469 |
MeSH ID | M0158971 |
Synonym |
---|
phenol, 2,3,5-trichloro- |
2,3,5-trichlorophenol |
NCGC00091770-01 |
933-78-8 |
einecs 213-272-2 |
ccris 6109 |
inchi=1/c6h3cl3o/c7-3-1-4(8)6(9)5(10)2-3/h1-2,10 |
2,3,5-trichlorophenol, analytical standard |
MLS002415681 |
smr001370875 |
NCGC00091770-03 |
NCGC00091770-02 |
HMS3039J12 |
unii-6t7duc2c8b |
6t7duc2c8b , |
tox21_200624 |
dtxcid206208 |
dtxsid0026208 , |
cas-933-78-8 |
NCGC00258178-01 |
AKOS006228272 |
FT-0609447 |
CL8455 |
trichlorophenol, 2,3,5- |
SCHEMBL591469 |
AM84112 |
CHEMBL1569358 |
phenol,2,3,5-trichloro- |
mfcd00002164 |
phenol, 2,3,5-trichloro-; 2,3,5-trichlorophenol |
2,3,5-trichlorophenol 10 microg/ml in isooctane |
2,3,5-trichlorophenol 100 microg/ml in methanol |
2,3,5-trichlorphenol |
DS-9219 |
Q2682869 |
CS-W021014 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID886 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID886 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 81.6590 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 28.5538 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
TDP1 protein | Homo sapiens (human) | Potency | 20.5962 | 0.0008 | 11.3822 | 44.6684 | AID686979 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 31.3871 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 46.5609 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259381; AID588515; AID588516; AID743035; AID743036; AID743042; AID743054; AID743063 |
Smad3 | Homo sapiens (human) | Potency | 17.7828 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 19.9526 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
PINK1 | Homo sapiens (human) | Potency | 50.1187 | 2.8184 | 18.8959 | 44.6684 | AID624263 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 0.3162 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 70.2671 | 0.0010 | 22.6508 | 76.6163 | AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 31.3871 | 0.0004 | 17.9460 | 75.1148 | AID1346784 |
glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 30.3152 | 0.0002 | 14.3764 | 60.0339 | AID588532; AID720692 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 59.2204 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 31.6228 | 0.0008 | 17.5051 | 59.3239 | AID588546 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 59.1283 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 44.6684 | 0.3758 | 27.4851 | 61.6524 | AID588526 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 62.6256 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 53.4642 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID743078; AID743079 |
Parkin | Homo sapiens (human) | Potency | 50.1187 | 0.8199 | 14.8306 | 44.6684 | AID624263 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 15.8489 | 0.0010 | 19.4141 | 70.9645 | AID588537 |
aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 24.0107 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 62.6256 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 29.2715 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
tumor necrosis factor | Homo sapiens (human) | Potency | 74.9780 | 0.3758 | 23.4928 | 42.1632 | AID651757 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 6.3096 | 0.0018 | 15.6638 | 39.8107 | AID894 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 79.4328 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 56.2341 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 68.9443 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 64.0251 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID743202; AID743219 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 10.0000 | 0.0079 | 8.2332 | 1,122.0200 | AID2551 |
geminin | Homo sapiens (human) | Potency | 15.8429 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 15.8489 | 0.0200 | 10.7869 | 31.6228 | AID912 |
Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 70.2671 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 64.4156 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 70.2671 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 18.8336 | 0.0266 | 22.4482 | 66.8242 | AID651802 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (12.50) | 18.7374 |
1990's | 1 (12.50) | 18.2507 |
2000's | 2 (25.00) | 29.6817 |
2010's | 3 (37.50) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.27) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |